D (more than 6 months) Fluorescent Proteins/lacZ System true Ppp3cc遺伝子のfloxedマウス (Knockout-first) 。精巣で強く発現するPpp3cc遺伝子のエクソン3がloxP配列で挟まれている。Ppp3cc gene floxed mice (Knockout-first). D（6か月以上） 条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Science, 350, 442-445 (2015).<br>使用範囲は学術機関の学術研究に限る。本系統のモデルマウスはEUCOMMコンソーシアムのベクターを使用して寄託者により作製された。利用者はベクターの提供元であるEUCOMMコンソーシアムに謝辞を表明する。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。5年経過後も使用を希望するときは改めて寄託者から承諾を得るものとする。 Ppp3cc gene floxed mice (Knockout-first). RBRC05878 EGR-G101 [C57BL/6NCr-Tg(CAG/Acr-EGFP)C3-N01-FJ002Osb] En2 splice acceptor (mouse En2 intron 2/exon 3 splice acceptor sequence), Encephalomyocarditis virus (EMCV) internal ribosomal entry site (ires), E. coli LacZ, SV40 polyadenylation site, hBactP (human beta-actin promoter), E. coli neomycin phosphotransferase (neoR) gene, yeast FRT (flipase recombination target) sites, phage P1 loxP, mouse Ppp3cc genomic DNA【クラス１】(以下「残存有」を交配にて取り除く)Jellyfish GFP cDNA, CAG promoter (chicken beta-actin promoter, rabbit beta-globin poly A, CMV-IE enhancer), mouse proacrosin promoter, mouse proacrosin signal peptide, acrosin N-terminal peptide, bovine growth hormone polyadenylation signal【クラス１】 FLP/frt system Ppp3cc KO, Ppp3cc floxed#12B Ppp3cc KO, Ppp3cc floxed#12B STOCK Ppp3cc<tm1a(EUCOMM)Osb>/12B STOCK Ppp3cc<tm1a(EUCOMM)Osb>/12B Ppp3cc遺伝子のfloxedマウス (Knockout-first) 。精巣で強く発現するPpp3cc遺伝子のエクソン3がloxP配列で挟まれている。,Ppp3cc gene floxed mice (Knockout-first). 伊川　正人 Developed by Dr. Masato Ikawa, Research Institute for Microbial Diseases, Osaka University in 2012. 大阪大学微生物病研究所 伊川正人先生 (2012） Masahito IKAWA Cre/loxP system Developmental Biology Research Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>CAGGS MTA (<A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/CAGGS_MTA.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol><A HREF="https://egr.biken.osaka-u.ac.jp/achievement/bio_resources" target="_blank">Lab HP</A> Heterozygote x Wild-type [or Crossing to Jcl:B6D2F1] Heterozygote x Wild-type [or Crossing to Jcl:B6D2F1] The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Science, 350, 442-445 (2015).Using the BIOLOGICAL RESOURCE is limited to the academic research of academic institutions. These strains were established by the DEPOSITOR by using knockout vectors of EUCOMM Consortium. The RECIPIENT shall acknowledge the EUCOMM Consortium as the source of the vectors of the strains. The RECIPIENT must contact in advance the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.　The RECIPIENT which wants to use the BIOLOGICAL RESOURCE even after five years must obtain a written consent from the DEPOSITOR again.